Bellicum announces publication of data for gocar-nk™ cell program

Houston, may 27, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of preclinical data from its gocar-nk™ cell program in the digital edition of blood advances, a journal published by the american society of hematology. the article is titled “inducible myd88/cd40 synergizes with il-15 to enhance antitumor efficacy of car-nk cells.”  bellicum’s proprietary inducible myd88/cd40 (imc) activation switch is incorporated into its gocar product candidates. in this study, incorporating imc into car-nk cells was found to improve cell proliferation and persistence, stimulate cytokine production, and enhance innate cytotoxicity against tumor cells in multiple models.  
BLCM Ratings Summary
BLCM Quant Ranking